Marishka DeToy

Marishka DeToy is a partner in the firm’s Business Law department and a member of its Life Sciences group.

Marishka has a broad capital markets practice representing issuers and underwriters in a range of transactions, including initial public offerings, follow-on public offerings, high-yield and investment-grade bond offerings, ATMs, PIPEs and tender offers. She also represents public and private companies in their ongoing corporate matters, including SEC compliance and corporate governance.

Marishka’s experience includes, among others, representation of:

• Prime Medicine, Inc. in its $175 million initial public offering
• BioDelivery Sciences International in its definitive acquisition by Collegium Pharmaceutical for $604 million
• BeiGene in its $3.5 billion initial public offering on STAR Market of the Shanghai Stock Exchange in China
• Vaccitech plc in its $40 million acquisition of Avidea Technologies
• The underwriters in Alphatec’s $316.2 million convertible note offering
• The underwriters in Omega Therapeutics’ $125.8 million initial public offering
• Monte Rosa Therapeutics in its $222.3 million initial public offering
• Vaccitech plc in its $110 million initial public offering
• Vaccitech plc in its $168 million Series B financing
• argenx NV in its $557 million and $1.15 billion follow-on offerings
• Goldman Sachs as lead underwriter in Taysha Gene Therapies, Inc.’s $181 million initial public offering
• BeiGene in its $2.08 billion registered direct offering and $340 million follow-on offering
• The underwriters in Evelo Biosciences’ $72.6 million follow-on offering
• Fusion Pharmaceuticals Inc. in its $212.5 million initial public offering
• The underwriters in SQZ Biotechnologies Company’s $70 million initial public offering and $60 million follow-on offering
• scPharmaceuticals in its $50 million follow-on offering
• Avadel Pharmaceuticals in its $65 million financing transaction and $125 million follow-on offering
• Black Diamond Therapeutics in its $231.3 million initial public offering
• Black Diamond Therapeutics in its $85 million Series C financing
• BeiGene in its $2.7 billion global strategic collaboration with Amgen
• Celyad SA in its $20 million follow-on offering and $32.5 million private placement
• Bicycle Therapeutics in its $60 million initial public offering
• BioDelivery Sciences International in its $60 million follow-on offering
• Kaleido Biosciences in its $75 million initial public offering
• Aerpio Pharmaceuticals in its $45 million follow-on offering

Marishka has been recognized as a “Rising Star” in The Legal 500 2022 in the Healthcare: Life Sciences category.